iraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial in Japa
Not Applicable
- Conditions
- ACS patient with type II diabetes
- Registration Number
- JPRN-UMIN000006817
- Lead Sponsor
- Department of Cardiovascular Medicine, Saga University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
patients will be excluded from the study when they meet to any of the criteria. (1)patients with cardiogenic shock (2)patient with serious liver disease((AST)GOT/(ALT)GPT>100) (3)patient with serious kidney trouble.(Cre>5mg/dl and patients under dialysis) (4)Patients with a past history of drug allergy and hypersensitivity. (5)Pregnant and/or breast-feeding at present,or a woman of child-bearing potential. (6)Patients with malignant neoplasms (7)Iinsulin-requiring diabetics.(Type 1,or type 2 with depletion of insulin secretion capacity.) (8)patients who was diagnosed that his/her condition is not appropriate to join this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1)Biomarker of cardiovascular disease (NT-proBNP,high sensitive troponin T,hs-CRP,MCP-1,eGFR,cystatinC,(S)-RAGE,MDA-LDL,AIM,etc) and shift of UACR (2)Changes in left ventricular function (left ventricular ejection rate, left ventricular volume, diastolic function)(3)change in HbA1c,FBS (4)safeness
- Secondary Outcome Measures
Name Time Method